Last updated on October 2018

Evaluation of Major Cardiovascular Events in Patients With or at High Risk for Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Brief description of study

The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.

Clinical Study Identifier: NCT02993406

Contact Investigators or Research Sites near you

Start Over

Maggie Horner

Pointe-Claire, QC Canada
  Connect »